Investigational Drug Information for APG-1252
✉ Email this page to a colleague
What is the drug development status for APG-1252?
APG-1252 is an investigational drug.
There have been 8 clinical trials for APG-1252.
The most recent clinical trial was a Phase 1 trial, which was initiated on March 1st 2022.
The most common disease conditions in clinical trials are Small Cell Lung Carcinoma, Lung Neoplasms, and Endometrial Neoplasms. The leading clinical trial sponsors are Ascentage Pharma Group Inc., Suzhou Yasheng Pharmaceutical Co., Ltd., and National Cancer Institute (NCI).
There are two US patents protecting this investigational drug and nineteen international patents.
Summary for APG-1252
| US Patents | 2 |
| International Patents | 19 |
| US Patent Applications | 12 |
| WIPO Patent Applications | 1 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2022-03-01) |
| Vendors | 10 |
Recent Clinical Trials for APG-1252
| Title | Sponsor | Phase |
|---|---|---|
| Testing the Combination of APG-1252 and Cobimetinib in Recurrent Ovarian and Endometrial Cancers | National Cancer Institute (NCI) | Phase 1 |
| APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma | Ascentage Pharma Group Inc. | Phase 1/Phase 2 |
| A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors | Ascentage Pharma Group Inc. | Phase 1 |
Clinical Trial Summary for APG-1252
Top disease conditions for APG-1252
Top clinical trial sponsors for APG-1252
US Patents for APG-1252
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| APG-1252 | ⤷ Try a Trial | BCL-2/BCL-XL inhibitors and therapeutic methods using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (Ann Arbor, MI) | ⤷ Try a Trial |
| APG-1252 | ⤷ Try a Trial | Bcl-2/Bcl-xL inhibitors and therapeutic methods using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (Ann Arbor, MI) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for APG-1252
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| APG-1252 | Australia | AU2014207716 | 2033-01-16 | ⤷ Try a Trial |
| APG-1252 | Canada | CA2897055 | 2033-01-16 | ⤷ Try a Trial |
| APG-1252 | China | CN105246882 | 2033-01-16 | ⤷ Try a Trial |
| APG-1252 | China | CN110302205 | 2033-01-16 | ⤷ Try a Trial |
| APG-1252 | China | CN110305162 | 2033-01-16 | ⤷ Try a Trial |
| APG-1252 | European Patent Office | EP2945940 | 2033-01-16 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
